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Ecarin is derived from venom of Echis carinatus and will activate prothrombin into 
meizothrombin which will then cleave fibrinogen to result in clot formation. Ecarin based 
testing has been described for decades, but these assays were typically restricted to reference 
or speciality coagulation laboratories.  This test was initially described for the assessment of 
direct thrombin inhibitors (e.g bivalirudin lepirudin, or argatroban) and was not affected by 
heparins or heparinoids. Ecarin based assays were rarely used for anticoagulation monitoring 
until the emergence of the direct oral thrombin inhibitor dabigatran etexilate in 2010. As this 
test was mentioned in the prescribing information for dabigatran etexilate, there was increased 
interest for use by clinical laboratories as the preferred method for assessing the anticoagulant 
effect of this drug. The purpose of this document is to review the current status of ecarin based 
assays for assessing dabigatran, with the understanding that these methods can also be 
exploited for determining the anticoagulation effect of parenteral direct thrombin inhibitors 
such as argatroban and bivalirudin. 
Introduction 
The first published report on the effect of envenomation from the saw-scaled viper, Echis 
carinatus demonstrated significant bleeding at wound site, petechiae, conjunctival hemorrhage 
and eventual death.1 The early stages of assessing Echis carinatus effect was in experimental 
observations after toxin exposure in white rats where the thrombin time prolongation was 
more pronounced than the Quick prothrombin time method, and thromboelastographic 
changes noted in dogs, 24 hours after toxin exposure. The authors presumed the effect was 
targeting either “the conversion to fibrinogen or fibrinolysis”, with the author suggesting ecarin 
primary mechanism being the latter effect.2 Later, it was demonstrated that Echis carinatus 
venom converts prothrombin to thrombin, but the venom itself lacking thrombin-like activity.3,4 
The resultant thrombin produced from Echis carinatus toxin (coined “ecarin”), was thought to 
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be of different properties than that achieved through normal physiologic processes and 
described as ecarin-thrombin or E-thrombin, a metalloprotease.5 In a series of experiments, the 
authors demonstrated the effect of ecarin was at two cleavage sites: one at the Arg-Ser bond, 
which is split during the release of the NH2-terminal portion of the molecule, the second being 
the Arg-Ile bond, which links the A-and B chain thrombin precursors.5 Later it was 
demonstrated that there was no Arg-Ser bond cleavage6 but that ecarin creates, rather than 
thrombin, meizothrombin which is a thrombin analogue consisting of α-thrombin complexed 
with prothrombin fragment 2, which is generated from cleavage at the Arg323-Ile324 site and has 
increased esterase activity.7  In contrast, the physiological activation of prothrombin by factor 
Xa occurs at cleavage site A (Arg273-Thr274, generating prothrombin fragment 1.2) in addition to 
cleavage site B (Arg322-Ile323).8 Note that the prothrombin fragment 2 generated by 
meizothrombin and prothrombin fragment 1.2 generated by factor Xa cleavage are not the 
same peptides. [Figure 1] 
As ecarin is an activator of prothrombin, the potential for clinical use was described in various 
settings including vitamin K deficiency9 and lupus anticoagulant testing10, using either 
chromogenic or clot-based methods. However, the utilization of ecarin based assays for 
anticoagulant assessment were fairly limited to research or reference laboratories, but the ECT 
is commonly used for lupus anticoagulant testing in certain geographical regions.11,12  In 1998, 
the FDA approved lepirudin (Refludan®, Bayer Healthcare), a recombinant hirudin, for 
treatment of heparin induced thrombocytopenia13, representing the first parenteral direct 
thrombin inhibitor (DTI) inhibiting both thrombin and meizothrombin.14,15 Shortly thereafter, 
other parenteral DTIs were approved, including bivalirudin and argatroban.14  The use of ecarin 
based testing now became of more interest as a local based assay, as DTIs became the standard 
of care for anticoagulating patients with heparin-induced thrombocytopenia.16   Ximelagatran, 
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an oral direct oral thrombin inhibitor was also reported to be suitably measured by ecarin 
based assays17, but this drug was removed from the market due to hepatotoxicity.18 
The real explosion for ecarin based testing emerged with the approval of dabigatran etexilate 
(Pradaxa®, Boehringer Ingelheim), a direct oral thrombin inhibitor, approved for use in the US in 
2010 as an alternative to warfarin for stroke prevention in patients with nonvalvular atrial 
fibrillation 19 Since 2010, additional FDA approved indications for dabigatran include treatment 
of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been 
treated with a parenteral anticoagulant for 5-10 days; risk reduction for recurrence of DVT and 
PE in patients who have been previously treated; and prophylaxis of DVT and PE in patients 
who have undergone hip replacement surgery20  The timing of approval was different in Europe 
where the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery 
was approved in 2008, and in 2014 approval was granted for the treatment of deep venous 
thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a 
parenteral anticoagulant for 5-10 days, or for risk reduction for recurrence of DVT and PE in 
patients who have been previously treated.  The current dosing indications are for adult 
patients and predicated on indication and renal function.18,21 In a study evaluating the 
prescribing practice in the US, Ziakas and colleagues demonstrated that in 2015, DOACs 
consisted of ~30% of the oral anticoagulants prescribed for medicare patients.22  Dabigatran 
constituted approximately 16 – 19% of DOAC prescriptions, mostly by cardiologists and internal 
medicine physicians.22   
While dabigatran is not monitored with the same frequency as warfarin, the need to measure 
dabigatran may be required for assessing bleeding patients, trauma, or patient requiring 
immediate intervention (thrombolysis in stroke, emergency surgery, neuraxial 
anesthesia).18,21,23  For dabigatran treated patients, ecarin based assays demonstrated a more 
linear response to drug concentration than the activated partial thromboplastin time (APTT) 
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with less inter-individual variations.24-28 In contrast, the traditional thrombin time (TT) is too 
sensitive for assessing dabigatran, with concentrations as low as 25 ng/mL resulting in a 2 to 3-
fold increase of the baseline TT, making this test more suitable for excluding drug presence 
instead of quantifying.26,27  Conversely, the Activated Clotting Time (ACT) has been shown to be 
less sensitive to dabigatran, with a misprediction as high as 40%.28  As ecarin methods are not 
affected by heparin, this method would even be suitable for monitoring transition therapy 
to/from heparins to dabigatran.26 
Ecarin tests are based on two different principles, i.e. clot-based and chromogenic-based 
methods.24 The purpose of this document is to review the testing principles of ecarin based 
assays as well as their application in the monitoring of anticoagulation. We will only focus on 
this application as these tests are now primarily used for the assessment of oral or parenteral 
direct thrombin inhibitors. 
The ecarin clot-based assay, also named the ecarin clotting time 
Despite its description in the literature for decades, there is to date no standardization of the 
ecarin clotting time (ECT).29 As previously described, ecarin will activate prothrombin (factor II) 
creating meizothrombin, which will then convert fibrinogen to fibrin, the principle of all clot-
based testing. [Figure 2A]  Despite the simple test principle, the variations of testing include: 
sample dilution (yes or no), degree of dilution (ratio of sample to diluent), diluent type (saline 
or buffer), whether preincubation of sample or reagents at 37oC, and ecarin concentration.16,29-
32,  resulting in different sensitivity to dabigatran exposure and lower limits of 
quantitation.[Figure 3] Due to its simplicity, the ECT can be easily automated to modern 
coagulation analyzers, but necessary performance verification is required, especially to assure 
absence of pipet/pipetting carryover of ecarin reagent. 
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Dabigatran etexilate prescribing information indicates that “At recommended therapeutic 
doses, dabigatran etexilate prolongs the coagulation markers such as aPTT, ECT, and TT.”20 
Additionally, the prescribing information indicates,  “In the RE-LY trial, the median (10th to 90th 
percentile) trough ECT in patients receiving the 150 mg dose was 63 (44 to 103) seconds.”20 The 
readers should be informed that the RE-LY trial was assessing the use of dabigatran in 
nonvalvular atrial fibrillation (NVAF). The dose for that indication may differ than dose for 
patients with reduced renal function or for other indications, and thus, the expected dabigatran 
concentration, and resultant ECT may differ.18,21  A technical procedural note mentioned that 
the ecarin concentration used for testing in the RE-LY trial was 6 IU/mL.35 However, there was 
no mention on the dilution ratio of the plasma and thus the final concentration of ecarin. 
Numerous studies have demonstrated the linearity of the ECT with dabigatran concentration. 
Most of the publications from Boehringer Ingelheim scientists used ecarin clotting time 
(expressed as a  
ratio)24,36-38,31-33, whereas one publication detailed the comparison between ECT with raw 
clotting times versus calibrated method to quantify dabigatran levels, with an estimated lower 
limit of quantitation around 25 ng/mL.39 Another study revealed that the ECT had a zero 
misprediction, indicating a prolongation of the ECT outside the normal reference interval for 
concentrations below 30 ng/mL.28 To date, the ECT has been largely used as a research tool 
with somewhat limited clinical availability in the USA. While development of commercial kits 
may improve the practicality of this test, these kits have not been standardized or validated 
with dabigatran. It has also to be noted that low levels of prothrombin or hypofibrinogenemia 
will cause falsely elevated conventional clotting times unproportionate to dabigatran or DTI 
concentrations. For these reasons, ECT cannot be recommended for emergency monitoring of 
anticoagulant effects even if this test is reported in current prescribing information. 
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The ecarin chromogenic assay 
As with ECT, the use of chromogenic ecarin testing has been described for decades. The 
principle of chromogenic testing is simple (Figure 2B), with differences are noted between 
sample preparation, addition of a prothrombin buffer, and chromogenic substrate for 
meizothrombin used.29 There was only one single commercial kit available, the Ecarin 
Chromogenic Assay (ECA-H/T, “H” and “T” standing for hirudin and DTI, respectively; 
HaemoSys-Ecarin Chromogenic Assay, dist. by Diagnostica Stago) that was designed for use as a 
means of monitoring DTI anticoagulation.40,41 Differences between the hirudin and the DTI 
methodology resided in the initial dilution of the sample. Subsequently, that method was 
replaced by a modified version, the ECA-II (Diagnostica Stago, Parsippany, NJ) in 2015. While 
both kits were distributed by Diagnostica Stago, there were differences between the two 
chromogenic ECA methods, as the ECA-H/T kit was designed for microplate techniques, and the 
ECA-II using an automated instrument platform. (Table 1) Adaptation to an automated analyzer 
was successfully accomplished using ECA-T method, suggesting a potential comparability 
between the two chromogenic assays.42 
In an unpublished study, samples from dabigatran treated patients were compared at 5 
different laboratory sites and tested using both ECA-T and ECA-II methods. For each site, 
calibration was performed using dabigatran calibrators (Hyphen Biomedical) for the ECA-T and 
dabigatran calibrators from Diagnostica Stago for the ECA-II method. Precision testing was 
performed by running two sets of dabigatran controls (Hyphen Biomedical and Diagnostica 
Stago) in duplicate over 5 days. Accuracy was assessed by analyzing plasma samples from 
dabigatran treated patients (CliniSys Associates, Ltd, Atlanta, GA) on both ECA methods. 
Notable differences between the two methods included the lower limit of quantitation (varied 
between site between 10 – 30 ng/mL) for ECA-T and ECA-II (15 ng/mL) and the raw data from 
calibration. (Figure 4) Each site was able to demonstrate precision of < 10.2% for control level I 
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(assigned control range around 50 ng/mL) and < 5.6% for control level II (around 200 ng/mL). 
Regression was demonstrated to be > 0.961 between ECA-II and assigned values for patient 
samples, with increasing bias associated with higher dabigatran levels, especially for the site 
using BCS-XP protocol, which consistently under recovered dabigatran levels when > 200 
ng/mL. The ECA-II did improve the accuracy of result recovery for all sites for samples with < 
100ng/mL (Figures 5), which has been previously noted.43 The improved accuracy at lower 
dabigatran concentration is most likely secondary to calibration methods, as ECA-T calibration 
used 3-4 points (0 [optional], 30, 255, and 468 ng/mL) and ECA-II had 5-point calibration curve 
(0, 52, 106, 182, and 270 ng/mL). These data, coupled with the protocol changes (Table 1) 
would suggest that protocol modifications are required to cover the entire testing range, but no 
change may be necessary if accuracy is more clinically relevant at lower dabigatran 
concentrations (<50ng/mL) for cases of emergent interventions.44,45 In addition, the 
methodology of Diagnostica Stago for the ECA-II assay uses reflex testing meaning that, when 
the concentration is above the higher calibration point, an automatic re-dilution of the samples 
is performed by the analyzer (from 1/5 in the initial analysis to 1/15 in the re-diluted analysis, 
increasing the potential range of measurement until 750 ng/mL approximatively). 
Point of care testing and ecarin 
More than 15 years ago, in order to rapidly monitor and evaluate the intensity of 
anticoagulation in patients treated with lepirudin, a point-of-care (POC) platform was created 
based on the activation of the coagulation process by the venom from Echis Carinatus.46 This 
test was based on the Thrombolytic Assessment System (TAS, Bayer Diagnostics; Rapidpoint 
Coag Analyzer, Morrisville, North Carolina) and employs the same coagulation principles as 
other ecarin clotting time assays, but in a 1-step, dry-chemistry platform. This test was 
commercialized by Pharmanetics but is now longer on the market. 
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Another microfluidic system based on the principle of lateral flow assays (LFAs), a new paper-
based method incorporating both ECA and ECT test platforms, has been reported to be 
sensitive towards the presence of dabigatran and other DTIs.47     This new system is based on 
the migration of the plasma on an electronegative environment of nitrocellulose fibers which 
mimics the exposed phospholipid surface of vascular endothelial cells, which slows down 
platelet aggregation and subsequent coagulation, suitable for clotting assays.  Microfluidic 
paper analytical devices (micro PAD’s) are more sophisticated and multichannel versions of 
LFAs are even more advantageous given small volume requirements, low operative costs, and 
design versatility.47 These paper-based lab-on-a-chip (LOC) platforms have gained increased 
clinical use as diagnostic tools, especially since these systems can work with smartphone 
applications to acquire data thanks to specific applications. However, while this technology may 
seem promising as a POC application, optimizations and validations are required to improve the 
sensitivity of this paper-based assay.47   
Thromboelastography has also emerged as one possible solution for the monitoring of DOACs. 
However, reagents triggering either the extrinsic or the intrinsic pathway were not sufficiently 
sensitive, nor robust. The use of ecarin in thromboelastography permits increasing the 
sensitivity, specificity and robustness of thromboelastography for the monitoring of DTIs in 
whole blood samples.48 Further investigations are still required for the viscoelastic 
measurement methods for the assessment of dabigatran.  A modified cartridge for the TEG6S 
(Haemonetics®, Braintree, MA), including an ecarin channel49, is currently under investigation 
(ClinicalTrials.gov, NCT02798328).  
Conclusion 
Ecarin is derived from the snake Echis carinatus and converts prothrombin to meizothrombin 
with the advantage of not being affected by heparin or heparinoids. While this test has been 
available for decades, it was rarely used by laboratories. However, the widespread approval of 
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the direct oral thrombin inhibitor, dabigatran etexilate, resulted in an emergence in this 
method, including citation in the prescribing information of Pradaxa. There are two different 
methodologies for ecarin based testing: the traditional clot-based assay and the chromogenic 
assay. It should be appreciated that the clot-based assay can be influenced by prothrombin and 
fibrinogen levels that may reduce the accuracy of the measurement of the inhibitory effect on 
thrombin. However, there is a high degree of specificity with ecarin based testing in the 
assessment of any direct thrombin inhibitor, including the parenteral drugs bivalirudin and 
argatroban. Dabigatran calibrated ecarin methods have been demonstrated to be equivalent to 
the gold standard method of mass spectrometry with the advantage of not being influenced by 
heparin which can be of interest in case of bridging or to ensure better specificity. The arrival of 
a POC device based on this venom may also provide rapid solutions to estimate the degree of 
anticoagulation in emergent situations.  While this manuscript describes Ecarin-based 
anticoagulant monitoring, the interested reader is referred to another current "Test of the 
Month" article on Ecarin-based lupus anticoagulant testing [Moore G, Am J Hematol]. 
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1. Ecarin based assays are highly sensitive and specific assays to assess the anticoagulant 
effect of oral and parenteral direct thrombin inhibitors. 
2. Ecarin is not affected by heparin or heparin-like anticoagulants, which is an advantage 
over the thrombin time, aPTT, and ACT, all of which are prolonged by heparin, 
interfering in  the measurement of DTIs when both anticoagulants are present or when 
heparin contamination occurs during specimen collection.   
3. There are two different ecarin assays: clot-based and chromogenic. 
4. Ecarin clot-based assays can be factitiously prolonged, and thus overestimating 
anticoagulant effect, in patients with reduced prothrombin (factor II) and fibrinogen 
levels. 
5. Dabigatran calibrated chromogenic ecarin assays have been demonstrated to be 
equivalent to mass spectrometry measurements. 
6. Ecarin assays have been demonstrated to be adaptable to current coagulation analyzers 
or transferred in a point-of-care (POC) device to provide rapid turn-around-time results 
for any direct thrombin inhibitor drug.   
a. The limitations of ecarin methods include the influence of  low prothrombin 
and/or fibrinogen levels, but these do not influence chromogenic ecarin assays 
b. There is a lack of standardization of ecarin assays, suggesting that ECT raw data 
(seconds) between methods may not be transferable. 
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Table 1: Comparison of STA-R Evolution protocol for ECA-T and ECA-II chromogenic ecarin methods.
ECA-T ECA-II
Sample dilution 1/10 1/5 (or 1/15)
Prothrombin buffer 
volume (µl) 140 140
Substrate reagent
volume (µl) 35 70
Ecarin reagent
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 Testing principles of ecarin clot based (A) and chromogenic based (B) testing18 
NOTE: As the ecarin clotting time (A) is dependent on patient prothrombin and fibrinogen levels, the clotting 
may be prolonged if prothrombin and/or low fibrinogen levels are present.  However, with the ecarin 
chromogenic assay, the sample is diluted in prothrombin buffer, eliminating the effect of low prothrombin 
levels, and the method is not dependent on fibrinogen conversion, and thus is not affected by low fibrinogen 
levels. 
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 Performance characteristics of ECT in dabigatran assessment 
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 Comparison of accuracy for samples containing <100ng/mL for ECA-T (A) and ECA-II (B) chromogenic 
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